AstraZeneca Merrem I.V. sNDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryAstraZeneca submits supplement July 28 for use of its broad-spectrum carbapenem antibiotic Merrem I.V. (meropenem) to treat complicated skin and skin structure infections. The submission is supported by a 1,076-patient Phase III trial in a range of infection types, as well as a pharmacokinetic study. Merrem is approved for treatment of intra-abdominal infections and bacterial meningitis...
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.